The results of the phase II and long-term follow-up treatment of MS patients with MBP8298.

The results of the phase II and long-term follow-up treatment of MS patients with MBP8298 , in 2006 in the European Journal of Neurology published showed that MBP8298 safely median time delayed progression to disease progression for five years . In progressive MS patients with HLA types DR2 and / or DR4 Sun dirucotide , if approved, has the potential to be tailored therapy for patients genetically determined to express the appropriate HLA molecules are used.

It also is for relapsing-remitting MS patients in a Phase II trial in Europe entitled MINDSET-01 are evaluated. In December 2007, BioMS license and development licensing and development agreement granting partner Eli Lilly and Company , the exclusive worldwide rights to dirucotide , in exchange for a $ 87,000 upfront payment, milestone payments and royalties on sales rising. For more information please visit our website at.. About BioMS Medical Corp.BioMS Medical a biotechnology company specializing in the development and commercialization of novel therapeutic technologies is employed. BioMS Medical ‘s lead technology, dirucotide for the treatment of multiple sclerosis in two in two phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the U.S.CARDIAC illnesses belong mellitus cardiovascular disease, type – 2 diabetes and metabolic syndrome. Targeted vitamin D deficiency in adults might gradually cardiometabolic the current outbreaks disorders. View 1990 to 2,009 from 1990 to 2009 with a which a majority 2,004 to 2009 half of the trials in the USA containing have been carried out, eight different European went to were two studies. From Iran.. A team of researchers with Warwick Medical School conducted a systematic literature search out of examinations of vitamin D and the cardiovascular disease.

Middle-aged and older persons to high levels of vitamin D may chances of developing chances of developing heart disease or diabetes by 43 percent, according to researchers from the University of Warwickshire.